MNPR Monopar Therapeutics Inc.
Healthcare$62.62-0.79%ClosedMarket Cap: $419.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.98
P/S
0.00
EV/EBITDA
-20.66
DCF Value
$7.99
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-12.8%
ROA
-10.9%
ROIC
-13.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-5.2M | $-3.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-6.2M | $-5.2M | $— | — |
| FY null | $0.00 | NaN% | $-16.7M | $-13.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.1M | $-3.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.2M | $-2.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.2M | $-2.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-11.1M | $-10.9M | $— | — |
| FY null | $0.00 | NaN% | $-16.2M | $-15.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.6M | $-1.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-1.8M | $-1.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.7M | $-1.6M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-1.9M | $-1.8M | $-0.12 | — |